TY - JOUR
T1 - The impact of substance use disorder on COVID-19 outcomes
AU - Baillargeon, Jacques
AU - Polychronopoulou, Efstathaia
AU - Kuo, Yong Fang
AU - Raji, Mukaila A.
N1 - Funding Information:
Department of Preventive Medicine and Population Health (all authors), and Department of Internal Medicine (Kuo, Raji), University of Texas Medical Branch, Galveston. Send correspondence to Dr. Baillargeon (jbaillar@utmb.edu). This study was supported by the Agency for Healthcare Research and Quality (T32HS02613301). Dr. Baillargeon has received consulting fees from AbbView, GlaxoSmithKline, Auxilium Pharmaceuticals, and Endo Pharmaceuticals. The other authors report no financial relationships with commercial interests. Received July 15, 2020; revisions received August 11 and August 19, 2020; accepted August 19, 2020; published online November 3, 2020.
Publisher Copyright:
© 2021 American Psychiatric Association. All rights reserved.
PY - 2021/5
Y1 - 2021/5
N2 - Objective: The goal of this study was to examine the impact of substance use disorder on the risk of hospitalization, complications, and mortality among adult patients diagnosed as having COVID-19. Methods: The authors conducted a propensity score (PS)-matched double-cohort study (N55,562 in each cohort) with data from the TriNetX Research Network database to identify 54,529 adult patients ($18 years) diagnosed as having COVID-19 between February 20 and June 30, 2020. Results: Primary analysis (PS matched on demographic characteristics and presence of diabetes and obesity) showed that substance use disorder was associated with an increased risk of hospitalization (odds ratio [OR]=1.84, 95% confidence interval [CI]=1.69-2.01), ventilator use (OR=1.45, 95% CI=1.22-1.72), and mortality (OR=1.30, 95% CI=1.08-1.56). Conclusions: The findings suggest that COVID-19 patients with substance use disorders are at increased risk for adverse outcomes. The attenuation of ORs in the model that matched for chronic respiratory and cardiovascular diseases associated with substance abuse suggests that the observed risks may be partially mediated by these conditions.
AB - Objective: The goal of this study was to examine the impact of substance use disorder on the risk of hospitalization, complications, and mortality among adult patients diagnosed as having COVID-19. Methods: The authors conducted a propensity score (PS)-matched double-cohort study (N55,562 in each cohort) with data from the TriNetX Research Network database to identify 54,529 adult patients ($18 years) diagnosed as having COVID-19 between February 20 and June 30, 2020. Results: Primary analysis (PS matched on demographic characteristics and presence of diabetes and obesity) showed that substance use disorder was associated with an increased risk of hospitalization (odds ratio [OR]=1.84, 95% confidence interval [CI]=1.69-2.01), ventilator use (OR=1.45, 95% CI=1.22-1.72), and mortality (OR=1.30, 95% CI=1.08-1.56). Conclusions: The findings suggest that COVID-19 patients with substance use disorders are at increased risk for adverse outcomes. The attenuation of ORs in the model that matched for chronic respiratory and cardiovascular diseases associated with substance abuse suggests that the observed risks may be partially mediated by these conditions.
UR - http://www.scopus.com/inward/record.url?scp=85105939336&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85105939336&partnerID=8YFLogxK
U2 - 10.1176/appi.ps.202000534
DO - 10.1176/appi.ps.202000534
M3 - Article
C2 - 33138712
AN - SCOPUS:85105939336
SN - 1075-2730
VL - 72
SP - 578
EP - 581
JO - Hospital and Community Psychiatry
JF - Hospital and Community Psychiatry
IS - 5
ER -